



Corrigendum

Corrigendum to “PRAK-03202: A triple antigen virus-like particle vaccine candidate against SARS CoV-2”[Heliyon 7 (10) (October 2021) e08124]



Saumyabrata Mazumder¹, Ruchir Rastogi¹, Avinash Undale¹, Kajal Arora¹, Nupur Mehrotra Arora¹, Biswa Pratim, Dilip Kumar, Abyson Joseph, Bhupesh Mali, Vidya Bhushan Arya, Sriganesh Kalyanaraman, Abhishek Mukherjee, Aditi Gupta, Swaroop Potdar, Sourav Singha Roy, Deepak Parashar, Jeny Paliwal, Sudhir Kumar Singh, Aelia Naqvi, Apoorva Srivastava, Manglesh Kumar Singh, Devanand Kumar, Sarthi Bansal, Satabdi Rautray, Manish Saini, Kshipra Jain, Reeshu Gupta, Prabuddha Kumar Kundu*

Premas Biotech Private Limited, Manesar, Gurugram, India

In the original published version of this article, sections “Cloning and expression of “S,” “E,” and “M” proteins”, “Transformation in D-Crypt™”, “Expression and Purification of PRAK-03202”, “Immunoblot”, “SEC-HPLC analysis”, “Dynamic Light Scattering Analysis”, “Electron microscopy” and “Binding affinity of PRAK-03202” were inadvertently omitted in the Materials and Methods section. This has now been added. In addition, under the section “Mice” in the Materials and Methods section, the text has been amended from to “All immunization experiments were performed using the high-performance liquid chromatography (HPLC)-purified form of PRAK-03202” to “All immunization experiments were performed using purified form of PRAK-03202”. Finally, two references that were omitted have now been added:

Ma, D., Chen, C.B., Jhanji, V., Xu, C., Yuan, X.L., Liang, J.J., Huang, Y., Cen, L.P., and Ng, T.K. (2020). Expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in human primary conjunctival and pterygium cell lines and in mouse cornea. *Eye* 34, 1212-1219

Rao, K.N., Suman, S.K., Kiran, Y.R., Kuanr, A.R., Gupta, A.K., Bhalla, K., Kumar, V., Kundu, P., Arora, K., and Soni, R. (2010). Co-expression of recombinant human CYP2C9 with human cytochrome P450 reductase in protease deficient *S. cerevisiae* strain at a higher scale yields an enzyme of higher specific activity. *Drug Metabol. Lett.* 4, 246-253

The authors apologize for the errors. Both the HTML and PDF versions of the article have been updated to correct the errors.

DOI of original article: <https://doi.org/10.1016/j.heliyon.2021.e08124>.

* Corresponding author.

E-mail address: prabuddha.kundu@premasbiotech.com (P.K. Kundu).

¹ These authors contributed equally.

<https://doi.org/10.1016/j.heliyon.2021.e08201>

Received 14 October 2021; Accepted 14 October 2021

2405-8440/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).